Grail, Inc. (NASDAQ:GRAL) Short Interest Update

Grail, Inc. (NASDAQ:GRAL) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,530,000 shares, a growth of 6.6% from the October 15th total of 3,310,000 shares. Based on an average trading volume of 750,800 shares, the short-interest ratio is currently 4.7 days. Currently, 13.5% of the company’s shares are sold short.

Grail Trading Down 5.4 %

Shares of NASDAQ:GRAL traded down $0.80 on Monday, reaching $14.00. The company had a trading volume of 1,377,515 shares, compared to its average volume of 1,096,653. Grail has a 52-week low of $12.33 and a 52-week high of $23.36. The business has a 50 day moving average of $13.82.

Insider Activity at Grail

In related news, CEO Robert P. Ragusa sold 123,454 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the completion of the sale, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at approximately $8,589,507.22. This represents a 16.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Chun R. Ding bought 7,629 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was bought at an average price of $13.52 per share, for a total transaction of $103,144.08. Following the completion of the purchase, the insider now owns 3,503,655 shares of the company’s stock, valued at approximately $47,369,415.60. The trade was a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 58,829 shares of company stock worth $757,298 over the last ninety days.

Analysts Set New Price Targets

GRAL has been the topic of a number of recent analyst reports. Wolfe Research assumed coverage on shares of Grail in a report on Friday. They issued a “peer perform” rating on the stock. Guggenheim began coverage on Grail in a research note on Thursday, October 17th. They issued a “neutral” rating on the stock.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.